Trials / Completed
CompletedNCT00203034
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 472 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rasagiline mesylate | 0.5 mg rasagiline mesylate oral once daily |
| DRUG | 1.0 mg rasagiline mesylate | 1.0 mg rasagiline mesylate oral once daily |
| OTHER | Placebo | oral placebo once daily |
Timeline
- Start date
- 2000-05-01
- Primary completion
- 2003-01-01
- Completion
- 2003-01-01
- First posted
- 2005-09-20
- Last updated
- 2010-03-09
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00203034. Inclusion in this directory is not an endorsement.